M&A / Deals Lilly, Gilead lead pharma’s M&A boom BioPharma DiveDeal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs.Read full story pharminent May 8, 2026 (Last updated: May 10, 2026) BioPharma Dive Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs. Read full story Post navigation Previous: Biogen, Eisai hit with 3-month delay for starting SubQ Alzheimer’s therapyNext: Pulsesight reports positive phase 1 data for PST611 in dry AMD Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
